Axsome Therapeutics (AXSM) is trading higher as investors react to a strong commercial quarter and multiple program catalysts clustered around the company’s CNS franchise. The company reported total Q1 2026 net product revenue of $191.2 million, representing 57% year-over-year growth, driven primarily by AUVELITY net product revenue of $153.2 million (+59% year over year) alongside SUNOSI net product revenue of $33.9 million (+34%) and SYMBRAVO net product revenue of $4.1 million.

Beyond sales growth, attention is centered on the FDA’s April 2026 approval of AUVELITY for agitation associated with dementia due to Alzheimer’s disease and the planned full commercial launch in June 2026. Investors are also weighing a newly submitted NDA for AXS-12 for cataplexy in narcolepsy, with the company indicating it plans to announce the FDA’s decision on acceptance of the filing.

Axsome reported a Q1 2026 net loss of $64.5 million, or $(1.26) per share, as spending rose with commercialization and pre-launch activity; SG&A increased to $185.0 million from $120.8 million a year earlier, and R&D rose to $52.7 million from $44.8 million, including a one-time acquisition-related expense. The company ended Q1 with $305.1 million in cash and cash equivalents and said current cash is sufficient to fund anticipated operations into cash-flow positivity based on the current operating plan.

Traders will monitor early uptake signals from the AUVELITY Alzheimer’s agitation rollout heading into June 2026, updates on FDA acceptance timing for the AXS-12 NDA, and any incremental detail from management appearances at upcoming investor conferences on May 12, 2026 and May 19, 2026. Continued prescription trends for AUVELITY, SUNOSI, and SYMBRAVO—and whether payer coverage expands as expected—remain central to sustaining the stock’s move.